Advertisement

A Neurologist’s View of Nausea and Vomiting

  • J. D. Parkes
Conference paper
Part of the Advances in Applied Neurological Sciences book series (NEUROLOGICAL, volume 3)

Abstract

The mechanisms (and treatment) of sickness depend on the cause. Some of the neurological causes of vomiting are the following (see also Table 1):
  1. 1.

    Migraine. Classic migraine attacks are characterised by nausea, and also by gastric stasis. Intense pain may contribute to gastric stasis, which may be the cause of the sensation of nausea, and may or may not lead to vomiting. Moreover, it is possible that the effect of analgesics is increased by administration of an anti-emetic.

     
  2. 2.

    Raised intracranial pressure. Vomiting may be sudden and forceful, but more often is preceded by severe nausea. Relief of raised pressure (e.g. surgery, dexamethasone) relieves sickness within a few days.

     
  3. 3.

    Low brain-stem focal gliomas. These may cause severe and persistent vomiting, with or without nausea, in the early stages, and without raised intracranial pressure, pointing to a vomiting centre in man localized in the low medulla.

     
  4. 4.

    Vestibular disorders. Vomiting is a common feature in ear disease, Meniere’s disease, vestibular neuronitis. Anticholinergic and antihistaminic, but not antidopaminergic, drugs give relief.

     

Keywords

Anorexia Nervosa Dopamine Agonist Ergot Alkaloid Temporal Arteritis Decarboxylase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agid Y, Pollak P, Bonnet AM, Signoret JL, Lhermitte F (1979) Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson’s disease. Lancet 1: 570–572PubMedCrossRefGoogle Scholar
  2. Bateman DN, Kahn C, Davies DS (1980) The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol 9: 371–377PubMedGoogle Scholar
  3. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276: 374–379PubMedCrossRefGoogle Scholar
  4. Debontrïdder O (1980 a) Extra-pyramidal reactions due to domperidone. Lancet 2:802 Debontrïdder O (1980b) Dystonic reactions after domperidone. Lancet 2:12–59Google Scholar
  5. Gonce M, Bury J, Burton L, Delwaide PJ (1982) Syndrome neurodysleptique induit par le domperidone. Nouv Presse Med 11: 22–98Google Scholar
  6. Klingler M (1982) A glimpse into Roche research: antiparkinsonian treatment. Int J Clin Pharmacol Ther Toxicol 20: 190–193PubMedGoogle Scholar
  7. Loew DM, Van Deusen EB, Meier-Ruge W (1978) Effects on the central nervous system. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, pp 421–531Google Scholar
  8. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1: 345–349PubMedCrossRefGoogle Scholar
  9. Matthews B (1963) Practical neurology. Blackwell, OxfordGoogle Scholar
  10. Moruzzi G (1972) The sleep-waking cycle. Ergeb Physiol 64: 1–165PubMedGoogle Scholar
  11. Quinn N, Illas A, Lhermitte F, Agid Y (1981) Bromocriptine and domperidone in the treatment of Parkinson’s disease. Neurology (NY) 31: 662–667Google Scholar
  12. Shindler J, Finnerty G, Jenner P, Lake-Bakaar G, Parkes JD (1984) Domperidone, metoclopramide and levodopa in Parkinson’s disease. Proceedings of First Symposium of the European Neuroendocrine Association, 4–7 March, Basle, p 42Google Scholar
  13. Sol P, Pelet B, Guignard JP (1980) Extrapyramidal reactions due to domperidone. Lancet 2: 802CrossRefGoogle Scholar
  14. Van Daele CM, Dobosz-Cyklis R, Van de Cassege W, Verbeek P, Wijndaele L (1984) Refusal of further cancer chemotherapy due to antiemetic drug. Lancet 1: 57CrossRefGoogle Scholar
  15. Volans GN (1975) The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 2: 57–63PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • J. D. Parkes
    • 1
  1. 1.Department of Neurology, King’s College Hospital and Institute of PsychiatryUniversity of LondonLondonUK

Personalised recommendations